Bristol Myers Squibb's RYZ101 meets primary endpoint in phase 3 GEP-NET trial

October 12, 2026 6:55 AM

Bristol Myers Squibb (NYSE: BMY) announced that its investigational radiopharmaceutical RYZ101 met the primary endpoint in the planned interim analysis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found